Category - Developments

CNBC has highlighted Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine in a feature about the treatment of opioid addiction and the crisis of fatal overdoses in the U.S. The feature...

Profound Medical (TSX-V:PRN) has made the first sale of its TULSA-PRO device to ResoFus Alomar in Barcelona, Spain. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral...

Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has reported first quarter revenue of $17.7-million, up 52%, from $11.7-million a year ago. Total direct sales in the quarter rose by $6.1-million, or 71%, and total...

Ocular Therapeutix (NASDAQ:OCUL) has completed an end-of-Phase 2 review with the FDA for its sustained release travoprost product candidate, OTX-TP, for the treatment of glaucoma and ocular hypertension and intends to...

Transition Therapeutics (NASDAQ:TTHI, TSX:TTH) has dosed the first patient in a Phase 2 study of selective androgen receptor modulator (SARM) drug candidate, TT701. The Phase 2 study will evaluate the efficacy and...

An article in the latest issue of Guernica, a magazine of art and politics, details the plight of doctors prescribing buprenorphine, a medication for the treatment of opiate addiction. Unlike methadone, buprenorphine...

Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months. The Phase 1/2a trial is an...

The FDA has advised TransEnterix (NYSE MKT:TRXC) that its SurgiBot System does not meet the criteria for substantial equivalence based on the data and information submitted by the company in its 510(k) submission. “The...

Titan Pharmaceuticals (NASDAQ:TTNP) has presented data from the last Phase 3 study of Probuphine, a six month subdermal buprenorphine implant for the long-term maintenance treatment of opioid addiction, at a poster...

Avivagen (TSX-V:VIV) plans to collaborate with the Jintai group of companies for a joint venture to commercialize OxC-beta Livestock in China. The companies plan to create a Sino-Canadian joint venture company based in...